Sentences with phrase «purchasing of additional shares»

3) Since they're not on automatic investing, I can re-balance my portfolio monthly through my purchasing of additional shares of one ETF and not as many in another

The DRIP allows shareholders to compound their investment through the convenient automatic purchase of additional shares without incurring commissions.

Many people believe that reinvested mutual fund dividends are simply taxable income and don't see them as a purchase of additional shares.

An offer given to current shareholders allowing the purchase of additional shares or securities before it's offered to the public.

Of course, if Mr. Market offers me a further 30 or 40 % discount over current prices I may have a hard time resisting the purchase of additional shares.

With a DRIP, you can reinvest the dividends that you earn back into the company that you own stock in, through the purchase of additional shares of stock in the company.

The agreed upon use of income dividends or capital gains distributions for the purchase of additional shares in a fund or company.

Not exact matches

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

«However, Berkshire routinely assesses market conditions and may decide to purchase additional shares of common stock of Wells Fargo based on its evaluation of the investment opportunity presented by such purchases.»

Bellicum expects to grant the underwriters of the offering a 30 - day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Pursuant to the offering, Centene granted the underwriters an option to purchase from the Company up to an additional $ 260 million in shares of common stock.

Charoen gained the upper hand when he amassed a stake of more than 40 percent in F&N by purchasing an additional 90.8 million shares, or a 6.3 percent stake in F&N, at S$ 9.55 each on Friday and another 2.2 million shares on Saturday.

There were also employee share options outstanding to purchase up to an additional 3.4 million shares, at a weighted average exercise price of $ 31.37 per share, 0.8 million of which were fully vested; equity - settled share appreciation rights (SARs) for 0.2 million shares, at a weighted average measurement price of $ 32.18, all of which, excluding SARs for approximately 1,000 shares, were fully vested; and restricted share units (RSUs) covering 13.0 million shares, of which RSUs to acquire 4.3 million shares were fully vested.

Should the deal's underwriters exercise an option to purchase up to 2.4 million additional shares, Ardagh said it could raise as much as $ 372.6 million (352.2 million euros) at the top of its price range.

DALLAS, April 19, 2017 / PRNewswire / — NexPoint Credit Strategies Fund (NYSE: NHF)(the «Fund») today announced the commencement of a non-transferable rights offering to purchase additional shares of common stock of the Fund (the «Offering») as the Fund's registration statement has been declared effective by the Securities and Exchange Commission.

In connection with the acquisition of XA Secure, the Company also issued 265,012 shares of restricted stock, issued 318,966 options to purchase the Company's common stock and may be required to pay an additional $ 3.92 million to certain key employee - shareholders of XA Secure.

(d) by causing Retrophin to pay cash to himself, Biestek, and Fernandez so that he would not have to invest $ 731,778 of his own funds in the February PIPE, and by using PIPE proceeds in contravention of the terms of the Securities Purchase Agreement to fund investments by Shkreli, Biestek and Fernandez, resulting in an additional benefit to Shkreli alone of $ 360,000 in cash and 180,000 Retrophin shares and warrants worth more than $ 5.3 million (at current market prices).

In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares.

The table above does not include (i) 5,952,917 shares of Class A common stock reserved for issuance under our 2015 Incentive Award Plan (as described in «Executive Compensation — New Employment Agreements and Incentive Plans»), consisting of (x) 2,689,486 shares of Class A common stock issuable upon exercise of options to purchase shares of Class A common stock granted on the date of this prospectus to our directors and certain employees, including the named executive officers, in connection with this offering as described in «Executive Compensation — Director Compensation» and «Executive Compensation — New Equity Awards,» and (y) 3,263,431 additional shares of Class A common stock reserved for future issuance and (ii) 24,269,792 shares of Class A common stock issuable to the Continuing SSE Equity Owners upon redemption or exchange of their LLC Interests as described in «Certain Relationships and Related Party Transactions — SSE Holdings LLC Agreement.»

If any additional shares of Class A common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.

You will experience additional dilution when those holding options exercise their right to purchase common stock under our equity incentive plans, when RSUs vest and settle, when we issue restricted stock to our employees under our equity incentive plans, or when we otherwise issue additional shares of our common stock.

Except as otherwise indicated, the discussion and the tables above assume no exercise of the underwriters» option to purchase additional shares of Class A common stock.

The table assumes no exercise by the underwriters of their option to purchase additional shares of Class A common stock.

The adjustment assumes there will be no additional distribution in the event the gross proceeds from the offering exceed the anticipated gross proceeds (including as a result of the exercise by the underwriters of their option to purchase additional shares of Class A common stock).

The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares.

The Company's board of directors also approved an additional distribution to its members, to the extent the gross proceeds of the Company's planned initial public offering exceed the anticipated gross proceeds (including as a result of the exercise by the underwriters of their option to purchase additional shares of Class A common stock), in an amount equal to the product of (A) the increased gross proceeds and (B) 0.273, to be paid from the proceeds of the Company's planned initial public offering.

On the date the shares subject to this offering are priced, each non-employee director who, as of the date of this offering, is serving on our board of directors and is expected to continue his or her service following this offering will be granted (a) an option to purchase shares of our Class A common stock with a grant date fair value of $ 50,000 (or, if such director is unaffiliated with any significant stockholder of the Company, $ 75,000) and (b) to the extent such director is (i) unaffiliated with any significant stockholder of the Company and (ii) the chairman of any committee of our board of directors, an additional option to purchase shares of our Class A common stock with a fair value of $ 10,000 with respect to each such chairmanship.

The diagram below depicts our organizational structure immediately following this offering assuming no exercise by the underwriters of their option to purchase additional shares of Class A common stock.

Upon the completion of this offering and after giving effect to the planned recapitalization of our common stock into a single class of common stock and stock split, SIH will own shares of our outstanding common stock (representing % of the shares outstanding), our founders and their family trusts will own an aggregate shares of our outstanding common stock (representing % of the shares outstanding) and our employees who received shares upon the liquidation of the special purpose employee ownership vehicle will own shares of our outstanding common stock under a restricted stock award (representing % of the shares outstanding), in each case as it relates to the percentage ownership assuming that the underwriters do not exercise their option to purchase additional shares.

Our principal stockholders, funds affiliated with or related to Cyrus Capital Partners, L.P. (which we refer to in this prospectus collectively as «Cyrus Capital») and affiliates of Virgin Group Holdings Limited (which we refer to in this prospectus collectively as the «Virgin Group»), as selling stockholders, have granted the underwriters an option to purchase up to additional shares of common stock at the initial public offering price less the underwriting discount solely to cover overallotments.

Following the 2014 Recapitalization, we may have additional outstanding warrants to purchase shares of our common stock.

QS Investors LLC now owns 75,620 shares of the biopharmaceutical company's stock worth $ 2,358,000 after purchasing an additional 3,771 shares in the last quarter.

American International Group Inc. now owns 51,539 shares of the biopharmaceutical company's stock worth $ 1,607,000 after purchasing an additional 2,255 shares in the last quarter.

William Blair Investment Management LLC now owns 1,762,619 shares of the medical device company's stock worth $ 101,157,000 after purchasing an additional 344,294 shares in the last quarter.

The Company has granted the Agents an over-allotment option, exercisable in whole or in part, for a period of 30 days following the closing of the Offering, to purchase up to an additional 4,726,500 Units at $ 3.65 per Unit, 4,726,500 Common Shares at the price of $ 3.62 per Share or 2,363,250 Warrants at the price of $ 0.06 per Warrant, or any combination thereof.

Victory Capital Management Inc. now owns 485,087 shares of the insurance provider's stock valued at $ 33,422,000 after purchasing an additional 70,992 shares during the period.

Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662 shares of the biopharmaceutical company's stock worth $ 145,000 after purchasing an additional 2,698 shares in the last quarter.

AXA now owns 1,911,206 shares of the medical device company's stock worth $ 109,684,000 after purchasing an additional 592,275 shares in the last quarter.

OppenheimerFunds Inc. now owns 1,495,535 shares of the medical device company's stock worth $ 85,829,000 after purchasing an additional 734,325 shares in the last quarter.

The firm owned 20,436 shares of the insurance provider's stock after purchasing an additional 7,731 shares during the quarter.

Crestline Management LP now owns 68,856 shares of the biopharmaceutical company's stock worth $ 2,147,000 after purchasing an additional 3,437 shares in the last quarter.

Fisher Asset Management LLC now owns 11,872,530 shares of the payment services company's stock worth $ 1,179,061,000 after purchasing an additional 325,140 shares during the last quarter.

BlackRock Inc. now owns 43,090,501 shares of the payment services company's stock worth $ 4,279,318,000 after purchasing an additional 781,329 shares during the last quarter.

Geode Capital Management LLC now owns 7,700,608 shares of the payment services company's stock worth $ 763,153,000 after purchasing an additional 382,691 shares during the last quarter.

When you purchase a dividend stock, you have the option of getting your dividends paid out to you or reinvesting them in additional shares.

Swiss National Bank now owns 119,600 shares of the biopharmaceutical company's stock worth $ 3,729,000 after purchasing an additional 2,800 shares in the last quarter.

Mackenzie Financial Corp now owns 1,371,595 shares of the medical device company's stock worth $ 78,716,000 after purchasing an additional 87,848 shares in the last quarter.

LPL Financial LLC now owns 47,874 shares of the company's stock worth $ 2,303,000 after purchasing an additional 15,441 shares during the period.

Ramsay Stattman Vela & Price Inc. now owns 84,028 shares of the conglomerate's stock worth $ 8,227,000 after purchasing an additional 550 shares in the last quarter.

FTB Advisors Inc. now owns 4,064 shares of the conglomerate's stock worth $ 386,000 after purchasing an additional 528 shares in the last quarter.